SEC Form 4 · accession 0001179110-17-009798
BeOne Medicines Ltd. · ONC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amy C. Peterson
Officer — CMO, Immuno-oncology
Period of report
Jun 27, 2017
Accepted (ET)
Jun 29, 2017 · 7:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001651308
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1,F2 | $3.49 | Jun 27, 2017 | A | 1,016,178 | A | — | Jun 26, 2027 | Ordinary shares | 1,016,178 | 1,016,178 | D |
Explanation of responses
- F1The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares.
- F2The options vest over a four-year period as follows: 25% on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal successive monthly installments on the last day of each month thereafter. Unvested options are subject to accelerated vesting upon certain termination events following a change in control.